Clinical Trials Logo

Filter by:
NCT ID: NCT05634655 Recruiting - Pituitary Tumors Clinical Trials

Dissecting the Mechanism of DNA Methylation on the Invasiveness of Pituitary Tumors.

Start date: January 1, 2022
Phase:
Study type: Observational

DNA methylation is one of the important ways of protein post-translational modification.Pituitary adenoma (PA) is a benign neuroendocrine tumor that originates from adenohypophysial 45 cells, and accounts for 10%-20% of all primary intracranial tumors. However some PAs can present with high invasiveness and irregular growth, which tend to compresses the optic chiasm and third ventricle, encase the internal carotid artery, and affect hormone secretion from the pituitary gland and hypothalamus. In this study we focus on the mechanism of DNA methylation on the invasiveness of pituitary tumors.

NCT ID: NCT05634616 Recruiting - Stroke Clinical Trials

Motor Imagery and Motor Execution Based BCI in Stroke

BCI-MIME
Start date: November 24, 2022
Phase: N/A
Study type: Interventional

About 50% of stroke patients are unable to live independently because of residual disability. Brain-computer interface (BCI) is based on closed-loop theory, which facilitates neurological remodeling by establishing a bridge between central and peripheral connections. Studies have confirmed that BCI real-time neurofeedback training system based on motor imagery alone can effectively improve patients' motor function. So, is the benefit greater if motor imagery is combined with motor execution? Current conclusions are mixed. In addition, previous studies and our preliminary study found that prefrontal Fp1 and Fp2 areas play an important role in motor recovery after stroke, and they are involved in motor imagery, motor execution, attention and other behavioral processes. Therefore, we designed a BCI training system based on motor imagery and motor execution with prefrontal electroencephalogram (EEG) signals as the modulatory target. This was a randomized placebo-controlled double-blinded clinical trial. Patients in the test group performed BCI-controlled upper extremity motor imagery + upper extremity pedaling training. The control group had the same equipment and training scenario, and patients were also asked to imagine the upper extremity pedaling movement with effort, and patients also wore EEG caps, but the EEG signals were only recorded without controlling the pedaling equipment. After 3 weeks of treatment, we observed the changes of motor and cognitive functions as well as fNIRS-related brain network characteristics in both groups.

NCT ID: NCT05634564 Recruiting - Clinical trials for Pancreatic Carcinoma

Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer

Start date: June 1, 2020
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the efficacy and safety of concurrent chemoradiotherapy combined with immunotherapy in patients with potentially resectable pancreatic cancer.

NCT ID: NCT05634408 Recruiting - Visual Acuity Clinical Trials

Evaluating ACUVUE® Abilitiā„¢ 1-Day Soft Therapeutic Lenses for Myopia Management

Start date: December 24, 2022
Phase: N/A
Study type: Interventional

This is a single-site, prospective, single-arm, open-label, real-world evidence study with a minimal study duration of 1-year, up to 2-year follow-up to evaluate overall visual acuity.

NCT ID: NCT05634382 Recruiting - Clinical trials for Stroke, Acute Ischemic

Endovascular Thrombectomy With and Without Intravenous Thrombolysis in Extended Time Window

Start date: December 3, 2022
Phase: Phase 3
Study type: Interventional

The primary hypothesis being tested in this trial is that ischemic stroke patients in large vessel occlusion of anterior circulation at 4.5 - 9 hours post onset of stroke will have improved clinical outcomes when given endovascular thrombectomy with intravenous thrombolysis compared with that of given direct endovascular thrombectomy alone.

NCT ID: NCT05633914 Recruiting - Clinical trials for HR+/HER2- Breast Cancer

Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer

Start date: February 7, 2023
Phase: Phase 2
Study type: Interventional

This study is looking to see whether the combination of Tucidinostat and nab-paclitaxel is safe and effective in participants with advanced HR+/HER2- breast cancer.

NCT ID: NCT05633732 Recruiting - Echocardiography Clinical Trials

Developing Echocardiography Image Quality Management System Based on Deep Learning

Start date: December 30, 2022
Phase:
Study type: Observational

To develop an echocardiography image quality management system based on deep learning to achieve objective and accurate automatic echocardiography image quality control. A total of 2000 patients performing transthoracic echocardiography were prospectively enrolled in the Department of Ultrasound Medicine of the Affiliated Drum Tower Hospital with Medical School of Nanjing University. The data of 8 TTE view segmentations were collected, including the views of the parasternal long axis of the left ventricle (PLAX_LV), parasternal short axis of the large vessel level (PSAX_GV), parasternal short axis of the mitral valve level (PSAX_MV), parasternal short axis of the papillary muscle level (PSAX_PM), parasternal short axis of the apical level (PSAX_AP), apical four cavity (A4C), apical three cavity (A3C), apical two cavity (A2C). The data of 1500 patients were used as the training set, and the rest were used as the validation set. These video data were classified into corresponding view segmentations and analyzed by the Video Swin Transformed Model. Then, the scoring module of different view segmentations combined key frame extraction, image segmentation, video target recognition and video classification model were established. At the same time, the scores achieved by the automatic echocardiography image assessment system were compared with the artificial score. By constantly correcting and learning and eventually building an primary automated grading system. At last, the automatic echocardiography image assessment system was constructed and performed on the rest 500 patients.

NCT ID: NCT05633641 Recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Peripheral Blood Neoantigen Specific T Cells Predict the Efficacy of Immunotherapy for Esophageal Squamous Cell Carcinoma

Start date: October 19, 2022
Phase:
Study type: Observational

This is a single-center clinical and exploratory study. Peripheral blood tumor antigen-specific T lymphocytes of patients with resectable esophageal cancer treated with neoadjuvant chemotherapy combined with immunotherapy and patients with advanced or metastatic esophageal cancer treated with first-line chemotherapy were detected at different time points to predict ORR after neoadjuvant chemotherapy combined with immunotherapy for resectable esophageal cancer and pCR rate, DFS after radical resection and first-line metastasis of advanced esophageal cancer Therapy combined with immunotherapy for ORR, PFS and OS.

NCT ID: NCT05633212 Recruiting - Clinical trials for Binocular Vision Disorder

Binocular Vision Alternations and fMRI Activation After ICL Implantation for High Myopia

Start date: March 15, 2022
Phase:
Study type: Observational

Implantable collamer lens (ICL) is one of the most effective operation for high myopia. Due to refractive correction changed, and prism effect of the spectacle removed, in the early stage after ICL implantation, binocular function might be dysfunction, leading to asthenopia, blurred vision, double vision and so on. This study will recruit the high myopia subjects that scheduled for ICL implantation, purpose to investigate the binocular vision alternations and brain activation that impacted by ICL implantation.

NCT ID: NCT05632939 Recruiting - Gastric Cancer Clinical Trials

ASKB589 in Combination With CAPOX and Sintilimab in Patients With Advanced, and Unresectable G/GEJ Cancer.

Start date: February 10, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This was an open-label, phase 1/2 study to evaluate safety, tolerability, pharmacokinetics, and antitumor activity of ASKB589 in combination with CAPOX and Sintilimab in first-line treatment of patients with locally advanced, recurrent, or metastatic gastric and esophagogastric junction adenocarcinoma.